
Harvard Bioscience, Inc. (NASDAQ:HBIO – Free Report) – Equities research analysts at Sidoti upped their FY2026 earnings per share estimates for Harvard Bioscience in a research note issued on Wednesday, November 11th. Sidoti analyst J. Sidoti now forecasts that the medical instruments supplier will post earnings per share of ($2.37) for the year, up from their previous forecast of ($2.44). The consensus estimate for Harvard Bioscience’s current full-year earnings is ($2.37) per share.
Harvard Bioscience (NASDAQ:HBIO – Get Free Report) last announced its quarterly earnings data on Tuesday, November 10th. The medical instruments supplier reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.27. The firm had revenue of $22.20 million during the quarter, compared to analyst estimates of $21.80 million. Harvard Bioscience had a negative net margin of 13.20% and a negative return on equity of 43.94%.
Get Our Latest Stock Analysis on HBIO
Harvard Bioscience Trading Down 0.2%
Shares of HBIO stock opened at $8.66 on Friday. The business has a fifty day simple moving average of $8.43 and a 200-day simple moving average of $6.68. The stock has a market cap of $39.58 million, a P/E ratio of -3.34 and a beta of 1.47. The company has a quick ratio of 0.86, a current ratio of 1.76 and a debt-to-equity ratio of 7.28. Harvard Bioscience has a fifty-two week low of $4.00 and a fifty-two week high of $10.20.
Institutional Trading of Harvard Bioscience
An institutional investor recently bought a new stake in Harvard Bioscience stock. Citadel Advisors LLC bought a new position in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 13,251 shares of the medical instruments supplier’s stock, valued at approximately $81,000. Citadel Advisors LLC owned 0.29% of Harvard Bioscience at the end of the most recent reporting period. 80.87% of the stock is currently owned by institutional investors.
Harvard Bioscience Company Profile
Harvard Bioscience, Inc. develops, manufactures and sells scientific instruments and equipment used in life science research. Its products support work in areas such as physiology, electrophysiology and preclinical research, and are used by academic and government institutions, biotechnology and pharmaceutical companies, and contract research organizations. The company’s offerings include laboratory instruments, equipment and related consumables, including systems for measuring biological activity and studying tissues, organs and cells.
Featured Articles
- Five stocks we like better than Harvard Bioscience
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
